Cybin Company Presentation

Medicinal (1) Forward-looking statements are subject to various risks and assumptions. See “Cautionary Statement Regarding Forward-Looking Information” on page 2 of this presentation. (2) There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesised process to obtain psilocybin and other analogues. WE AIM TO SCALE OUR SYNTHETIC API PRODUCTION FOR OUR OWN STUDIES, COMMERCIALIZATION OF OUR PRODUCTS AND TO LEVERAGE AS A REVENUE STREAM THROUGH APPROVED ACCADEMIC AND CORPORATE INSTITUTIONS WHO ARE IN NEED OF A SYNTHETIC API (1) Cybin is in the process of manufacturing its own API for clinical research into psychedelics, through its exclusive partnership with Smart Medicines GMP Inc in Canada. The initial focus will be psilocybin, but with the intention to expand to other analogues found within magic mushrooms. (1) (2) It currently takes academics around a year to get psilocybin for their studies, as they wait for local institutional review board approval, FDA approval, and DEA approval. Cybin has secured 25g API at GMP source which is available immediately and sufficient for GMP SL film manufacturing and clinical Phase 2a and Phase 2b trials in patients with moderate depressive disorder. The API can be shipped to any academic or research facility with a drug establishment license. INITIAL DEVELOPMENT OF OUR SYNTHETIC API IS EXPECTED FOR Q4 2020 (1) See page 17 for expected timelines Secured source of synthetic API Creation of our own proprietary API (1) 14 Phase 1 Phase 2 API Strategy P r i v a t e & C o n f i d e n t i a l